Sinusoidal Obstruction Syndrome: Causes, Symptoms, Treatment

Sinusoidal obstruction syndrome (SOS), historically called hepatic veno-occlusive disease, is a potentially life-threatening liver condition triggered when toxic agents destroy the tiny cells lining the liver’s blood-filtering channels. It occurs most often after high-dose chemotherapy given before a bone marrow or stem cell transplant, though certain plant toxins and chemotherapy drugs used for other cancers can cause it too. The name was updated in the early 2000s after research showed the real damage starts in the sinusoidal lining cells themselves, not primarily in the veins farther downstream, making the older name misleading.

What Actually Happens Inside the Liver

Your liver filters blood through a network of tiny channels called sinusoids, lined by specialized endothelial cells. In SOS, a toxic exposure strips away these lining cells. The central event is destruction of sinusoidal endothelial cells, which swell, detach, and float downstream, physically clogging the small veins that drain the liver. Contributing factors include depletion of glutathione (a protective molecule inside those cells), loss of nitric oxide, and activation of clotting factors that compound the blockage.

Animal studies have confirmed the sequence in detail. After toxic exposure, the endothelial cells swell within hours. The sinusoidal lining peels away, and clumps of detached cells act like emboli, blocking blood flow through the liver’s microcirculation. White blood cells then pile onto the obstruction, worsening the damage. Crucially, when glutathione was infused into the portal vein before or during exposure, it preserved the sinusoidal lining and prevented the syndrome entirely.

² ³

The name “sinusoidal obstruction syndrome” was proposed in 2002 to better reflect this pathology. Researchers argued that the older term, veno-occlusive disease, placed blame on the veins when the sinusoidal endothelial cells are clearly the primary target. You’ll still see both names used, often as “SOS/VOD,” because the older terminology persists in clinical guidelines and older literature.

⁴

What Causes It

The most common setting for SOS is myeloablative conditioning, the intensive chemotherapy given to wipe out a patient’s bone marrow before a stem cell transplant. Drugs like busulfan and cyclophosphamide are classic culprits. In one retrospective study of 372 patients who received oral busulfan and cyclophosphamide before an allogeneic transplant, about 7% developed SOS, typically appearing around 19 days after the transplant.

⁵

Outside the transplant setting, SOS has been linked to oxaliplatin, a platinum-based chemotherapy drug widely used for colorectal cancer. Oxaliplatin-induced SOS was initially recognized in patients receiving chemotherapy for liver metastases from colorectal cancer, though case reports have documented it in other cancers treated with the drug as well.

⁶

In parts of the world where traditional herbal remedies are common, SOS can occur after ingesting plants containing pyrrolizidine alkaloids. This is a significant cause in China, where certain herbal preparations used in traditional medicine contain these toxins. The clinical picture of pyrrolizidine alkaloid–induced SOS differs enough from the transplant-associated version that findings about diagnosis and treatment may not transfer directly between the two.

⁷

Who Is at Higher Risk

Not everyone receiving myeloablative conditioning develops SOS, so identifying who is vulnerable matters. Pre-existing liver disease, previous liver radiation, and certain conditioning regimens all raise the odds. Younger children are at higher risk than adults, and the disease looks different in the two groups in terms of how often it occurs, how it presents, and how it responds to treatment.

⁸

In the busulfan-cyclophosphamide study mentioned earlier, the transplant center introduced several changes over time to reduce toxicity: they stopped using a particular hormonal agent (norethisterone), started monitoring busulfan blood levels to keep them in a safer range, and added liver-supportive drugs like ursodeoxycholic acid and N-acetyl-L-cysteine. These stepwise changes appeared to help lower the incidence of SOS over the study period.

⁵

Recognizing the Symptoms

SOS typically shows up within the first three weeks after transplant conditioning, though a late-onset form can appear beyond that window. The hallmark triad is weight gain from fluid retention, painful enlargement of the liver, and rising bilirubin (the pigment that causes jaundice). In practice, patients notice their abdomen swelling, their skin or eyes turning yellow, and tenderness under the right rib cage. Severe cases progress to kidney failure, lung problems, and confusion as multiple organs begin to fail.

The diagnosis is clinical, meaning it relies on recognizing the pattern rather than on a single lab test. For decades, two sets of criteria were used: the Baltimore criteria and the modified Seattle criteria. Both were developed for adults after transplant. More recently, the European Society for Blood and Marrow Transplantation (EBMT) refined the adult classification to distinguish probable, clinical, and proven SOS at the time of diagnosis, and introduced a severity grading system based on how many organs are affected.

⁹

A validation study of the refined 2023 EBMT criteria found that the “clinical SOS/VOD” tier achieved 100% sensitivity with a specificity of about 98%, a marked improvement over the older modified Seattle criteria, which had sensitivity around 95% but specificity of only 75%. That jump in specificity matters because false positives in this context lead to unnecessary treatment with an expensive drug that carries its own bleeding risks.

¹⁰

Children get their own separate EBMT criteria because SOS behaves differently in younger patients. The incidence is higher, the genetic susceptibility profile differs, and the clinical presentation can be atypical enough that adult diagnostic frameworks miss cases or misclassify severity.

⁸

Early Detection With Imaging and Blood Markers

One of the frustrating things about SOS is that by the time symptoms are obvious, significant liver damage has already occurred. This has pushed research toward finding the disease earlier using imaging and blood biomarkers.

Liver stiffness measurement using ultrasound elastography has shown promise. Liver stiffness begins to climb days before the classic symptoms appear, which could open a window for earlier treatment. In patients who respond to therapy, stiffness drops back to pre-transplant levels within two to four weeks.

¹¹

On the blood-biomarker front, a large study from the Blood and Marrow Transplant Clinical Trials Network evaluated 23 candidate biomarkers. Ten showed a meaningful association with SOS risk at one or more time points after transplant. Hyaluronic acid (HA), a sugar molecule released when the sinusoidal lining is damaged, was the single strongest predictor, with strong prognostic accuracy by day 7 after transplant. Combining HA with other markers like ICAM-1 pushed accuracy even higher.

¹²

A separate prospective study zeroed in on a three-biomarker panel measured as early as day 3 after transplant: L-ficolin (a component of the innate immune system), HA, and ST2 (a marker of inflammation). Low L-ficolin levels carried roughly a nine-fold increased risk of developing SOS, while high HA and high ST2 carried about six- and five-fold increased risks, respectively. All three markers also predicted worse survival at day 100.

¹³

None of these biomarkers is yet part of standard diagnostic criteria, but they are moving in that direction. The practical implication for patients is that transplant centers doing serial biomarker monitoring may catch SOS earlier and initiate treatment sooner, which substantially affects outcomes.

Treatment With Defibrotide

Defibrotide is the only drug specifically approved for severe SOS with organ dysfunction. It is a complex mixture of single-stranded DNA fragments derived from pig intestinal tissue, and it works primarily by protecting and restoring the damaged endothelial cells lining the liver sinusoids. In laboratory studies, defibrotide reduces the pro-clotting activity of endothelial cells and boosts their ability to break down clots, tipping the balance away from the kind of vascular plugging that drives SOS.

¹⁴ ¹⁵

Beyond clot-related effects, defibrotide appears to dampen inflammation at the endothelial level. Research has shown it reduces signaling through pathways that drive the production of inflammatory molecules, which may help limit the cascade of damage that turns localized sinusoidal injury into multiorgan failure.

¹⁶

How well does it work in practice? A French registry study of 251 patients with severe or very severe SOS found that about 61% were alive at day 100 after transplant, and roughly 55% achieved complete resolution. The outcomes were considerably better in children (84% of pediatric patients achieved complete resolution) than in adults (46%). Patients with severe disease fared better than those with very severe disease, reinforcing the idea that catching and treating SOS before organ failure sets in makes a real difference. The most common serious side effects were infections (17% of patients) and hemorrhage (16%).

¹⁷

A Korean single-center study painted a more sobering picture for adults specifically. Among 73 adults with severe or very severe SOS treated with defibrotide, the overall response rate was about 47%, and the 100-day survival was roughly 34%. Patients who started defibrotide within two days of diagnosis had significantly better survival than those who started later, reinforcing a pattern seen across multiple studies: early treatment is critical.

¹⁸

Supportive Care and Fluid Management

Defibrotide gets the headlines, but careful supportive care is considered just as important, particularly in managing fluid balance. SOS causes the liver to leak fluid into the abdomen (ascites) and surrounding tissues, and the kidneys often begin retaining sodium and water. The resulting fluid overload can compromise breathing and kidney function. British guidelines recommend judicious management of fluid balance as a cornerstone of treatment and advise early involvement of critical care specialists and a hepatology unit.

¹⁹

In practice, supportive care means carefully monitoring daily weight, urine output, and kidney function; using diuretics cautiously to avoid making kidney injury worse; maintaining adequate nutrition; and managing pain from liver swelling. Paracentesis, the draining of accumulated abdominal fluid, is sometimes needed to relieve pressure and improve breathing.

When Drugs Aren’t Enough

For patients who don’t respond to defibrotide and supportive care, more invasive options exist. A transjugular intrahepatic portosystemic shunt (TIPS) is a procedure where a radiologist creates a channel inside the liver to relieve the pressure buildup. A systematic review and meta-analysis found that TIPS reduced portal vein pressure by a mean of about 12 mmHg, effectively relieving symptoms like ascites and abdominal swelling. The pooled three-month and one-year survival rates after TIPS both reached about 92%, suggesting it can meaningfully improve outcomes in patients who are failing medical therapy.

²⁰

Liver transplantation is reserved for the most refractory cases and is rarely performed in the transplant-associated SOS setting because these patients are typically immunosuppressed and dealing with the aftermath of their bone marrow transplant. It may be more practical in pyrrolizidine alkaloid–induced SOS or other non-transplant causes where the patient is otherwise in better shape. TIPS can serve as a bridge to transplant in suitable candidates.

¹⁹

Prevention Efforts

Given how difficult SOS is to treat once established, preventing it is the preferred strategy. Ursodeoxycholic acid (UDCA), a bile acid that protects liver cells, is widely used as prophylaxis in transplant centers. Some centers add an anticoagulant such as heparin on the theory that preventing microclot formation in the sinusoids might help. However, a study comparing UDCA alone to UDCA plus an anticoagulant found no significant difference in SOS incidence between the groups, either by the Seattle or Baltimore criteria. The combination did not reduce severe SOS either.

²¹

Therapeutic drug monitoring of busulfan has become standard practice at many centers and is arguably the single most impactful preventive measure for patients receiving that particular conditioning regimen. By measuring blood levels of busulfan and adjusting doses in real time, clinicians can keep the drug in a therapeutic range that destroys the marrow effectively without excessive liver toxicity.

⁵

Long-Term Outlook After Recovery

Most patients who survive the acute phase of SOS recover without lasting liver problems. Late complications are rare, though a small number of patients develop persistent liver fibrosis that can lead to long-term portal hypertension and its consequences, including esophageal varices.

²²

The outlook is different for SOS caused by oxaliplatin-based chemotherapy for colorectal liver metastases. In patients undergoing liver surgery after such chemotherapy, those who developed moderate-to-severe sinusoidal damage had roughly twice the risk of recurrence and nearly three times the risk of death compared to those without sinusoidal damage. They also had significantly more recurrences within the liver itself. This finding has practical implications for surgeons and oncologists deciding how long to give chemotherapy before operating.

²³

The Financial Toll

SOS is expensive to manage. A U.S. study found that transplant patients who developed SOS with organ dysfunction had an adjusted average hospital cost of about $141,000, roughly $42,000 more than transplant patients who did not develop SOS. Their hospital stays averaged about a week longer, and they had nearly six times the odds of dying during that hospitalization.

²⁴

Defibrotide itself adds substantially to the bill. A European single-center analysis found that the mean treatment cost per patient was about €33,000, with adult patients averaging roughly €104,000 per course compared to about €17,000 for children (reflecting both higher weight-based dosing and typically longer treatment durations in adults).

²⁵

These costs are part of why prevention and early detection command so much research attention. A biomarker panel that could reliably identify high-risk patients before symptoms emerge would allow targeted prophylaxis and earlier intervention, potentially avoiding the worst outcomes and the steep costs that accompany them.